- Home
- SGA vs UNCY Comparison
SGA vs UNCY Comparison
Compare SGA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- UNCY
- Stock Information
- Founded
- SGA 1986
- UNCY 2016
- Country
- SGA United States
- UNCY United States
- Employees
- SGA N/A
- UNCY N/A
- Industry
- SGA Broadcasting
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- UNCY Health Care
- Exchange
- SGA Nasdaq
- UNCY Nasdaq
- Market Cap
- SGA 78.8M
- UNCY 74.2M
- IPO Year
- SGA 1992
- UNCY 2021
- Fundamental
- Price
- SGA $12.94
- UNCY $4.63
- Analyst Decision
- SGA
- UNCY Strong Buy
- Analyst Count
- SGA 0
- UNCY 5
- Target Price
- SGA N/A
- UNCY $55.20
- AVG Volume (30 Days)
- SGA 5.9K
- UNCY 510.5K
- Earning Date
- SGA 11-06-2025
- UNCY 11-12-2025
- Dividend Yield
- SGA 7.69%
- UNCY N/A
- EPS Growth
- SGA N/A
- UNCY N/A
- EPS
- SGA 0.33
- UNCY N/A
- Revenue
- SGA $110,350,000.00
- UNCY N/A
- Revenue This Year
- SGA N/A
- UNCY N/A
- Revenue Next Year
- SGA $5.37
- UNCY $4,481.14
- P/E Ratio
- SGA $39.69
- UNCY N/A
- Revenue Growth
- SGA N/A
- UNCY N/A
- 52 Week Low
- SGA $10.75
- UNCY $3.40
- 52 Week High
- SGA $15.10
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- SGA 55.52
- UNCY 61.71
- Support Level
- SGA $12.08
- UNCY $3.72
- Resistance Level
- SGA $13.05
- UNCY $4.80
- Average True Range (ATR)
- SGA 0.36
- UNCY 0.24
- MACD
- SGA 0.10
- UNCY 0.07
- Stochastic Oscillator
- SGA 89.32
- UNCY 75.00
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.